Literature DB >> 9645198

Fowl adenovirus recombinant expressing VP2 of infectious bursal disease virus induces protective immunity against bursal disease.

M Sheppard1, W Werner, E Tsatas, R McCoy, S Prowse, M Johnson.   

Abstract

The right hand end Nde I fragment 3 (90.8-100 map units) of the fowl adenovirus serotype 10 (FAV-10) was characterised so as to allow the location of an insertion site for recombinant vector construction. Infectious bursal disease virus (IBDV) VP2 gene from the Australian classical strain 002/73, under the control of the FAV-10 major late promoter/leader sequence (MLP/LS) was inserted into a unique Not I site that was generated at 99.5 map units. This recombinant virus was produced without deletion of any portion of the FAV-10 genome. When administered to specific pathogen free (SPF) chickens intravenously, intraperitoneally, subcutaneously or intramuscularly, it was shown that the FAV-10/VP2 recombinant induced a serum VP2 antibody response and protected chickens against challenge with IBDV V877, an intermediate virulent classical strain. Birds were not protected when the recombinant was delivered via the conjunctival sac.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9645198      PMCID: PMC7087160          DOI: 10.1007/s007050050342

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  24 in total

1.  The genome of turkey herpesvirus.

Authors:  C L Afonso; E R Tulman; Z Lu; L Zsak; D L Rock; G F Kutish
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

2.  The genome of a very virulent Marek's disease virus.

Authors:  E R Tulman; C L Afonso; Z Lu; L Zsak; D L Rock; G F Kutish
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

3.  Canine adenovirus vectors: an alternative for adenovirus-mediated gene transfer.

Authors:  E J Kremer; S Boutin; M Chillon; O Danos
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

4.  Development of an effective polyvalent vaccine against both Marek's and Newcastle diseases based on recombinant Marek's disease virus type 1 in commercial chickens with maternal antibodies.

Authors:  K Sonoda; M Sakaguchi; H Okamura; K Yokogawa; E Tokunaga; S Tokiyoshi; Y Kawaguchi; K Hirai
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

5.  Sequence comparison of the right end of fowl adenovirus genomes.

Authors:  Juan Carlos Corredor; Amalia Garceac; Peter J Krell; Eva Nagy
Journal:  Virus Genes       Date:  2008-01-17       Impact factor: 2.332

Review 6.  Economically important non-oncogenic immunosuppressive viral diseases of chicken--current status.

Authors:  V Balamurugan; J M Kataria
Journal:  Vet Res Commun       Date:  2006-07       Impact factor: 2.459

7.  Complete, long-lasting protection against lethal infectious bursal disease virus challenge by a single vaccination with an avian herpesvirus vector expressing VP2 antigens.

Authors:  K Tsukamoto; S Saito; S Saeki; T Sato; N Tanimura; T Isobe; M Mase; T Imada; N Yuasa; S Yamaguchi
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

8.  Canine adenovirus type 2 attachment and internalization: coxsackievirus-adenovirus receptor, alternative receptors, and an RGD-independent pathway.

Authors:  C Soudais; S Boutin; S S Hong; M Chillon; O Danos; J M Bergelson; P Boulanger; E J Kremer
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

9.  A recombinant Newcastle disease virus (NDV) expressing VP2 protein of infectious bursal disease virus (IBDV) protects against NDV and IBDV.

Authors:  Zhuhui Huang; Subbiah Elankumaran; Abdul S Yunus; Siba K Samal
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

10.  Expression of immunogenic VP2 protein of infectious bursal disease virus in Arabidopsis thaliana.

Authors:  H Wu; N K Singh; R D Locy; K Scissum-Gunn; J J Giambrone
Journal:  Biotechnol Lett       Date:  2004-05       Impact factor: 2.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.